Trials / Recruiting
RecruitingNCT07284875
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,800 (estimated)
- Sponsor
- Kailera · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to determine the effects of KAI-9531 subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KAI-9531 | SC Injection |
| DRUG | Placebo | SC Injection |
Timeline
- Start date
- 2025-12-18
- Primary completion
- 2028-02-28
- Completion
- 2028-03-27
- First posted
- 2025-12-16
- Last updated
- 2026-03-02
Locations
22 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07284875. Inclusion in this directory is not an endorsement.